GlassScriptPhysician profile
Steven A Ellis
NPI 1124164504
$549.82
in general payments reported to CMS, 2019-2025
15 companies · $31.26 in 2025
The $31.26 reported for 2025 was less than what a typical Anesthesiology provider received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $74.03 · 2020: $37.20 · 2021: $41.06 · 2022: $17.02 · 2023: $212 · 2024: $138 · 2025: $31.26.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $381.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $380.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $181.25 | 2019-2024 | Bridion |
| Pfizer INC. | $47.55 | 2023-2024 | |
| Amneal Pharmaceuticals LLC | $45.61 | 2023-2024 | Rytary, Crexont |
| Ucb, INC. | $35.67 | 2023 | Briviact |
| Abbott Laboratories | $35.00 | 2024-2025 | Infinity |
| Axsome Therapeutics, INC. | $29.08 | 2023 | Sunosi |
| Intersect Ent, INC. | $28.46 | 2021 | |
| Atricure, INC. | $27.70 | 2023 | |
| Supernus Pharmaceuticals, INC. | $23.40 | 2019-2021 | |
| Alnylam Pharmaceuticals INC. | $21.88 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $17.76 | 2023 | Austedo |
| Livanova USA, INC. | $15.24 | 2025 | Vns Therapy Sentiva Model 1000 Generator |
| Portola Pharmaceuticals, LLC | $15.14 | 2019 | |
| Tanabe Pharma America, INC. | $14.67 | 2024 | |
| Strongbridge US INC. | $11.41 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Ellis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.